ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue protection. Key marketed products include ORTHOVISC (osteoarthritis), HYVISC (equine osteoarthritis), and various ophthalmic viscoelastic products (e.g., CoEase, AMVISC). The company recently entered into significant licensing agreements with Ortho Biotech (for ORTHOVISC) and OrthoNeutrogena (for cosmetic tissue augmentation).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 73.7% in Q3 2004 and 81.0% for the nine months ended Sep 30, 2004, compared to the prior year. This was driven by the launch of ORTHOVISC in the U.S. and increased ophthalmic sales.
• Profitability Surge: Net income for the nine months ended Sep 30, 2004, was $9.44 million, a massive increase from $26,000 in the prior year. This is primarily due to a one-time income tax benefit of $7.0 million resulting from the release of a valuation allowance against deferred tax assets.
• Deferred Revenue: Deferred revenue increased significantly to $23.76 million (current and long-term combined) from $2.18 million at year-end 2003. This includes a $20 million milestone payment from Ortho Biotech received in February 2004, which is being recognized ratably over 10 years.
• Operating Expenses: R&D expenses increased 105% in Q3 and 56% for the nine months, driven by clinical trials for cosmetic tissue augmentation (CTA) and INCERT. SG&A expenses increased 65% in Q3 due to personnel costs and Sarbanes-Oxley compliance fees.

Guidance, Outlook, and Risks

• ORTHOVISC Outlook: U.S. sales growth has been slower than anticipated due to reimbursement code issues. While a unique "C code" was assigned for hospital outpatient settings (effective Jan 2005), a unique "J code" for physician offices was not assigned. Management expects Q4 2004 U.S. sales to Ortho Biotech to be significantly lower than the first three quarters due to inventory buildup, though royalties may offset this.
• Ophthalmic Business: Sales are expected to decrease significantly in Q4 2004 compared to Q4 2003 because the company cannot replicate the deferred revenue recognized in the prior year's fourth quarter. Additionally, the agreement with distributor Advanced Medical Optics is expected to terminate in July 2005 following their acquisition of a competitor's business.
• Key Risks:
  • Reimbursement: Dependence on third-party payers and the assignment of specific reimbursement codes for ORTHOVISC.
  • Customer Concentration: Three customers accounted for 72.2% of product revenue for the nine months ended Sep 30, 2004.
  • Regulatory: Uncertainty regarding FDA approval for new products (CTA, INCERT) and potential delays in clinical trials.
  • Contractual: Potential loss of key distribution partners (e.g., Advanced Medical Optics) and price adjustments under the Bausch & Lomb agreement.

Investor Verification Checklist

• Tax Benefit Sustainability: Verify the one-time $7.0 million tax benefit and confirm that future profitability will not rely on similar non-recurring items.
• Reimbursement Codes: Monitor the status of the "J code" application for ORTHOVISC in physician offices, as the lack thereof may hinder market penetration.
• Deferred Revenue Recognition: Track the ratable recognition of the $20 million Ortho Biotech milestone and the $2.3 million OrthoNeutrogena payments over their respective contract terms.
• Ophthalmic Revenue Volatility: Assess the impact of the Bausch & Lomb volume-based pricing agreement on Q4 revenue recognition and the potential loss of Advanced Medical Optics as a distributor in 2005.
• Cash Burn vs. Cash Flow: While operating cash flow is strong, verify if the $34 million cash balance is sufficient to fund ongoing clinical trials and R&D without further dilution, given the high R&D spend.